1-3 of 3
Markus Y Mapara
Close
Sort by
Journal Articles

Absolute Lymphocyte Count after BCMA CAR-T Therapy is a Predictor of Response and Outcomes in Relapsed Multiple Myeloma

Mateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, Tarek H Mouhieddine, Juan Esteban Velez-Hernandez, Katherine Engles, Joshua Alexander Fein, Jorge Monge, Cara A Rosenbaum, Roger Pearse, David S. Jayabalan, Christian A Gordillo, Hei Ton Chan, Samuel Yamshon, Santiago Thibaud, Markus Y Mapara, Giorgio GA Inghirami, Suzanne Lentzsch, Ran Reshef, Adriana Rossi, Samir Parekh, Sundar Jagannath, Shambavi Richard, Ruben Niesvizky, Mark Bustoros
Journal: Blood Advances
Blood Adv bloodadvances.2023012470.
https://doi.org/10.1182/bloodadvances.2023012470
Published: 2024
Includes: Supplemental data
Journal Articles

Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects

Shirong Li, Jing Fu, Christopher J. Walker, Jun Yang, Divaya Bhutani, Rajshekhar Chakraborty, Niha Mamillapalli, Markus Y. Mapara, Yosef Landesman, Suzanne Lentzsch
Journal: Blood Advances
Blood Adv (2023) 7 (12): 2926–2937.
https://doi.org/10.1182/bloodadvances.2021006638
Published: 2023
Journal Articles

IMiD compounds affect CD34 + cell fate and maturation via CRBN-induced IKZF1 degradation

Shirong Li, Jing Fu, Hui Wang, Huihui Ma, Xiaoming Xu, Yong-Guang Yang, Shixian Deng, Markus Y. Mapara, Suzanne Lentzsch
Journal: Blood Advances
Blood Adv (2018) 2 (5): 492–504.
https://doi.org/10.1182/bloodadvances.2017010348
Published: 2018
Includes: Supplemental data